Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking or

Rezolute Reports Fourth Quarter and Full Year

Fiscal 2022 Results and Highlights Company Progress

Announced a $130 million registered direct offering

and concurrent private placement priced at-the-market

presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022

Phase 2 proof-of-concept

study of RZ402 expected to be initiated later this year

REDWOOD CITY, Calif., September 15, 2022 (GLOBE NEWSWIRE)

- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies

with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the fourth

quarter and full fiscal year ended June 30, 2022.

"This quarter marked steady progress as we continue to drive

our clinical programs forward, including RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema," said Nevan

Charles Elam, Chief Executive Officer and Founder of Rezolute. "With the $130 million financing that we completed, we are well-capitalized

to advance RZ358 into a Phase 3 trial and to initiate a Phase 2 proof-of-concept study for RZ402. We believe these candidates hold the

potential to create a new standard of care for patient populations in need of better therapeutic options."

Corporate and Clinical Highlights

Fourth Quarter and Full Year Fiscal 2022 Financial Results

About Rezolute, Inc.

Rezolute strives to disrupt current treatment

paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential

to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system.

Patient, clinician, and advocate voices are integrated in the Company's drug development process, enabling Rezolute to boldly address

a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients'

lives. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism,

a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking

statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E

of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions

for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for

purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans,

strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe,"

"estimate," "expect," "intend," "plan," "project," "seek," "strive,"

"try," or future or conditional verbs such as "could," "may," "should," "will," "would,"

or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly,

actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no

obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements

were made. Important factors that may cause such a difference include any other factors discussed in Rezolute's filings with the

SEC, including the Risk Factors contained in the Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,

which are available at the SEC's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking

statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their

entirety by this cautionary statement.

Kimberly Minarovich/Carrie McKim

Canale Communications, Inc.